CorMedix is a pharmaceutical company based in New Jersey, focused on developing therapeutic products, notably DefenCath, an antimicrobial solution for preventing catheter-related bloodstream infections in kidney failure patients. The company went public in 2010 and has also sponsored research on taurolidine for rare pediatric tumors.
CorMedix (CRMD) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, CorMedix's actual EPS was $0.22, beating the estimate of $0.14 per share, resulting in a 54.06% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
